{"product_id":"mazdutide","title":"Mazdutide","description":"\u003cdiv class=\"pb-product-desc\"\u003e\n\u003ch2\u003eMazdutide (LY3305677) — Dual GLP-1\/Glucagon Receptor Agonist for Metabolic Research\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eMazdutide\u003c\/strong\u003e (INN; also known as LY3305677) is a novel long-acting dual agonist peptide targeting both glucagon-like peptide-1 (GLP-1) and glucagon receptors. Developed by Innovent Biologics in collaboration with Eli Lilly, mazdutide has been the subject of multiple clinical trials published in \u003cem\u003eThe Lancet Diabetes \u0026amp; Endocrinology\u003c\/em\u003e and \u003cem\u003eNature Medicine\u003c\/em\u003e (2023-2024), demonstrating significant effects on body weight reduction and glycemic control. As a dual-action incretin analog, mazdutide provides researchers with a unique pharmacological tool for studying the synergistic metabolic effects of simultaneous GLP-1 and glucagon receptor engagement.\u003c\/p\u003e\n\n\u003ch3\u003eMechanism of Action\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eMazdutide\u003c\/strong\u003e is engineered as a peptide-Fc fusion construct with balanced agonist activity at both GLP-1R and GCGR. The GLP-1 receptor component activates Gs-coupled cAMP signaling in pancreatic beta cells, enhancing glucose-dependent insulin secretion, slowing gastric emptying, and activating hypothalamic satiety centers. Simultaneously, the glucagon receptor agonist component stimulates hepatic glycogenolysis, increases energy expenditure through thermogenesis in brown adipose tissue, and promotes hepatic lipid oxidation. The dual mechanism produces complementary metabolic effects—GLP-1R mediating appetite suppression and insulin secretion, while GCGR drives energy expenditure and fat oxidation.\u003c\/p\u003e\n\n\u003ch3\u003eKey Research Areas\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eWeight Management:\u003c\/strong\u003e Phase II\/III clinical trials have demonstrated that \u003cstrong\u003eMazdutide\u003c\/strong\u003e produces dose-dependent body weight reductions of 10-15% over 24-48 week treatment periods in obese subjects, with superior weight loss kinetics compared to GLP-1-only receptor agonists in head-to-head preclinical comparisons.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlycemic Control:\u003c\/strong\u003e Research has documented significant HbA1c reductions (1.5-2.0 percentage points) in type 2 diabetes models, with the dual agonism providing both insulin-dependent (GLP-1R) and insulin-independent (GCGR-mediated hepatic glucose output suppression) glycemic control mechanisms.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEnergy Expenditure:\u003c\/strong\u003e Indirect calorimetry studies have demonstrated increased resting metabolic rate and enhanced diet-induced thermogenesis following mazdutide administration, attributed to GCGR-mediated activation of brown adipose tissue UCP1 expression and hepatic FGF21 secretion.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHepatic Lipid Metabolism:\u003c\/strong\u003e Research has observed significant reductions in intrahepatic triglyceride content (measured by MRI-PDFF), decreased serum ALT levels, and improved NAFLD activity scores in preclinical NASH models treated with dual GLP-1\/glucagon agonists.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eTechnical Specifications\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eDosage per vial:\u003c\/strong\u003e 5mg lyophilized powder\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e ≥98% (HPLC verified)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e -20°C, protected from light\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eWhy Researchers Choose Peptides BioLab\u003c\/h3\u003e\n\u003cp\u003eEvery batch of \u003cstrong\u003eMazdutide\u003c\/strong\u003e supplied by Peptides BioLab undergoes rigorous HPLC and mass spectrometry analysis, ensuring ≥98% purity verified by an independent Certificate of Analysis (CoA). Our product is supplied as a lyophilized powder for maximum stability, shipped worldwide in temperature-controlled packaging.\u003c\/p\u003e\n\n\u003ch3\u003eRelated Research Peptides\u003c\/h3\u003e\n\u003cp\u003eResearchers studying incretin biology and metabolic regulation may also find these compounds relevant: \u003ca href=\"\/products\/aod9604\"\u003eAOD-9604\u003c\/a\u003e, \u003ca href=\"\/products\/5-amino1-mq\"\u003e5-Amino-1MQ\u003c\/a\u003e, and \u003ca href=\"\/products\/mots-c\"\u003eMOTS-c\u003c\/a\u003e. For a complete overview, browse our \u003ca href=\"\/collections\/weight-loss\"\u003eWeight Loss Research\u003c\/a\u003e collection.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eFor research purposes only — Not for human consumption. All products are intended solely for in-vitro research and laboratory use.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Peptides BioLab","offers":[{"title":"Default Title","offer_id":61420787532106,"sku":"PBL-MAZDUTIDE-5MG","price":39.99,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0998\/9429\/6906\/files\/peptides-biolab-mazdutide-peptide-5mg-research-grade.webp?v=1774393604","url":"https:\/\/peptides-biolab.com\/products\/mazdutide","provider":"Peptides BioLab","version":"1.0","type":"link"}